Placeholder Banner

BIO Comments on SEC Proposed Proxy Amendments

February 3, 2020

In comments to the Securities and Exchange Commission (SEC), BIO applauds the SEC for taking a proactive approach in amending the exemptions from the proxy rules for proxy voting. If adopted, the proposal will significantly improve proxy firm transparency without sacrificing investor protection. 

Download Full Comments Below
Final Comments on SEC Proposed Proxy Amendments
Discover More
February 14, 2020 Re: Docket No. FDA–2020-D-0529: FDA Draft Guidance, Qualification Process for Drug Development Tools Dear Sir/Madam:  The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA or Agency)…
Dear Administrator McCarthy, We write to request that the Environmental Protection Agency (EPA) update its greenhouse gas life-cycle emissions analysis for corn ethanol to include consideration of the current state of the industry and the published…
February 11, 2020 Re: Docket No. FDA–2019-D-4751: Food and Drug Administration Reauthorization Act Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs Dear Sir/Madam: The Biotechnology Innovation Organization (BIO…